[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100482949":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":20,"locations":21,"responsibleParty":107,"collaborators":20,"id":109,"slug":110,"hasResults":111,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":20,"eligibilityCriteria":115,"healthyVolunteers":111,"sex":116,"minAge":117,"maxAge":20,"enrollmentInfo":118,"targetDuration":20,"studyType":121,"phases":122,"briefSummary":124,"conditions":125,"keywords":20,"overallStatus":24,"whyStopped":20,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":138},{"fullName":5,"class":6},"Verismo Therapeutics","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"SynKIR-110","EXPERIMENTAL","Single dose gravity drip IV administration",[13],"Biological: SynKIR-110, Autologous T cells Transduced with Mesothelin KIR-CAR",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"BIOLOGICAL","SynKIR-110, Autologous T cells Transduced with Mesothelin KIR-CAR","Autologous T cells Transduced with Mesothelin KIR-CAR",[9],null,[22,45,56,73,90],{"facility":23,"status":24,"city":25,"state":26,"zip":27,"country":28,"countryCode":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":36},"Moffitt Cancer Center","RECRUITING","Tampa","Florida","33612","United States","US",{"type":31,"coordinates":32},"Point",[33,34],-82.45843,27.94752,{"lat":34,"lon":33},[37,42],{"name":38,"role":39,"phone":40,"phoneExt":20,"email":41},"Ashley O'Neil, MPH, LSSWB, CCRC","CONTACT","813-745-5240","Ashley.ONeil@moffitt.org",{"name":43,"role":44,"phone":20,"phoneExt":20,"email":20},"Ben Creelan, MD","PRINCIPAL_INVESTIGATOR",{"facility":46,"status":47,"city":48,"state":49,"zip":50,"country":28,"countryCode":29,"cosmosGeoPoint":51,"geoPoint":55,"contacts":20},"University of Kansas Cancer Center","ACTIVE_NOT_RECRUITING","Westwood","Kansas","66205",{"type":31,"coordinates":52},[53,54],-94.6169,39.04056,{"lat":54,"lon":53},{"facility":57,"status":24,"city":58,"state":59,"zip":60,"country":28,"countryCode":29,"cosmosGeoPoint":61,"geoPoint":65,"contacts":66},"University of Pennsylvania","Philadelphia","Pennsylvania","19104",{"type":31,"coordinates":62},[63,64],-75.16362,39.95238,{"lat":64,"lon":63},[67,71],{"name":68,"role":39,"phone":69,"phoneExt":20,"email":70},"Andrea Standish","215-662-2419","andrea.standish@pennmedicine.upenn.edu",{"name":72,"role":44,"phone":20,"phoneExt":20,"email":20},"Janos Tanyi, MD, PhD",{"facility":74,"status":24,"city":75,"state":76,"zip":77,"country":28,"countryCode":29,"cosmosGeoPoint":78,"geoPoint":82,"contacts":83},"MD Anderson Cancer Center","Houston","Texas","77030",{"type":31,"coordinates":79},[80,81],-95.36327,29.76328,{"lat":81,"lon":80},[84,88],{"name":85,"role":39,"phone":86,"phoneExt":20,"email":87},"Zheng Zhang","832-729-0975","ZZhang11@mdanderson.org",{"name":89,"role":44,"phone":20,"phoneExt":20,"email":20},"Mehmet Altan, MD",{"facility":91,"status":24,"city":92,"state":93,"zip":94,"country":28,"countryCode":29,"cosmosGeoPoint":95,"geoPoint":99,"contacts":100},"University of Wisconsin Carbone Cancer Center","Madison","Wisconsin","53792",{"type":31,"coordinates":96},[97,98],-89.40123,43.07305,{"lat":98,"lon":97},[101,105],{"name":102,"role":39,"phone":103,"phoneExt":20,"email":104},"Cancer Connect","800-622-8922","CancerConnect@uwhealth.org",{"name":106,"role":44,"phone":20,"phoneExt":20,"email":20},"Zhubin Gahvari, MD",{"type":108,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100482949","phase-1-synkir-110-for-mesothelin-expressing-ovarian-cancer-cholangiocarcinoma-or-mesothelioma-100482949",false,"NCT05568680","SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma","A Phase 1 Study of SynKIR-110, Autologous T Cells Transduced With Mesothelin KIR-CAR, in Subjects With Mesothelin-Expressing Advanced Ovarian Cancer, Cholangiocarcinoma, or Mesothelioma","Inclusion Criteria:\n\n* Pathologically confirmed recurrent or relapsed advanced ovarian cancer, primary peritoneal cancer, fallopian tube cancer, cholangiocarcinoma, or epithelial mesothelioma (pleural or peritoneal) after at least 1 prior line of systemic therapy for advanced disease\n* Adult 18 years of age or older.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.\n* Has at least 1 measurable lesion by iRECIST for ovarian cancer or cholangiocarcinoma or lesions measurable for mRECIST for mesothelioma.\n* Satisfactory Blood coagulation parameters\n* Satisfactory organ and bone marrow function\n\nExclusion Criteria:\n\n* Active invasive cancers other than mesothelioma, cholangiocarcinoma, and ovarian unless surgically and medically cured without evidence of recurrent disease for 5 years.\n* History of T or B cell malignancies or previous gene-engineered T cell therapies.\n* Sarcomatoid\u002Fbiphasic mesothelioma.\n* Pulmonary exclusions\n* Have acquired hereditary, congenital immunodeficiency or have recognized immunodeficiency disease\n* Active hepatitis B, active hepatitis C, or any HIV infection at the time of screening\n* Active autoimmune disease","ALL","18 Years",{"count":119,"type":120},42,"ESTIMATED","INTERVENTIONAL",[123],"PHASE1","This first-in-human (FIH) trial is designed to assess the safety, feasibility, and potential activity of a single intravenous (IV) dose of SynKIR-110 administered to subjects with mesothelin-expressing advanced ovarian cancer, mesothelioma, and cholangiocarcinoma.",[126,127,128],"Ovarian Cancer","Cholangiocarcinoma Recurrent","Mesothelioma, Malignant","2026-06-23",{"date":131,"type":132},"2026-06-24","ACTUAL",{"date":134,"type":132},"2023-03-30",{"date":136,"type":120},"2027-12",{"name":5,"class":6},5]